

## POST-TEST

### Oncology Today with Dr Neil Love: The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate (ADC) directed against which of the following targets?
  - a. Folate receptor alpha
  - b. CDH6
  - c. HER2
  - d. XPO1
2. What was the approximate objective response rate with R-DXd for platinum-resistant advanced ovarian cancer across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?
  - a. 15%
  - b. 25%
  - c. 50%
  - d. 85%
3. Which of the following adverse events is commonly associated with R-DXd?
  - a. Headache
  - b. Peripheral neuropathy
  - c. Thrombocytopenia
  - d. Nausea
4. Which of the following adverse events is the most commonly associated with sacituzumab govitecan?
  - a. Rash
  - b. Neutropenia
  - c. Constipation
  - d. Hyperkalemia
5. What was the objective response rate reported for patients with endometrial cancer in the Phase II TROPiCS-03 study evaluating sacituzumab govitecan for pretreated metastatic or locally advanced solid tumors?
  - a. 22%
  - b. 46%
  - c. 62%